表紙
市場調査レポート

TechnoPhage SA:製品パイプライン分析

TechnoPhage SA - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 319997
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
TechnoPhage SA:製品パイプライン分析 TechnoPhage SA - Product Pipeline Review - 2016
出版日: 2016年06月15日 ページ情報: 英文 30 Pages
概要

TechnoPhage SA はポルトガルのリスボンに拠点を置くバイオテクノロジー企業で、様々な疾患の治療薬を開発しています。特に、炎症性疾患、代謝性疾患、筋骨格疾患、アルツハイマー病やパーキンソン病、慢性潰瘍、感染症などの治療薬を提供し、単一ドメイン抗体断片の開発に力を入れています。また、製薬会社や様々な研究機関に対して研究開発サービスの提供も行っています。

当レポートでは、TechnoPhage SAにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

TechnoPhage SAの基本情報

  • TechnoPhage SAの概要
  • 主要情報
  • 企業情報

TechnoPhage SA:R&Dの概要

  • 主な治療範囲

TechnoPhage SA:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

TechnoPhage SA:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
  • IND/CTA に申請された製品/併用療法モダリティ
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

TechnoPhage SA:薬剤プロファイル

  • TP-102
  • TA-101
  • TA-141
  • TP-122
  • TZ-123
  • TA-111
  • TA-131
  • TP-107
  • TZ-113
  • TZ-121
  • TZ-134

TechnoPhage SA:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

TechnoPhage SA:休止中のプロジェクト

TechnoPhage SA:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08068CDB

Summary

Global Markets Direct's, 'TechnoPhage SA - Product Pipeline Review - 2016', provides an overview of the TechnoPhage SA's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by TechnoPhage SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of TechnoPhage SA
  • The report provides overview of TechnoPhage SA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses TechnoPhage SA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features TechnoPhage SA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate TechnoPhage SA's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for TechnoPhage SA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding TechnoPhage SA's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • TechnoPhage SA Snapshot
    • TechnoPhage SA Overview
    • Key Information
    • Key Facts
  • TechnoPhage SA - Research and Development Overview
    • Key Therapeutic Areas
  • TechnoPhage SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • TechnoPhage SA - Pipeline Products Glance
    • TechnoPhage SA - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • TechnoPhage SA - Drug Profiles
    • TA-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TZ-113
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TZ-121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TA-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TA-131
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-107
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-132
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TZ-151
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • TechnoPhage SA - Pipeline Analysis
  • TechnoPhage SA - Pipeline Products by Target
  • TechnoPhage SA - Pipeline Products by Molecule Type
  • TechnoPhage SA - Pipeline Products by Mechanism of Action
  • TechnoPhage SA - Dormant Projects
  • TechnoPhage SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • TechnoPhage SA, Key Information
  • TechnoPhage SA, Key Facts
  • TechnoPhage SA - Pipeline by Indication, 2016
  • TechnoPhage SA - Pipeline by Stage of Development, 2016
  • TechnoPhage SA - Monotherapy Products in Pipeline, 2016
  • TechnoPhage SA - IND/CTA Filed, 2016
  • TechnoPhage SA - Preclinical, 2016
  • TechnoPhage SA - Discovery, 2016
  • TechnoPhage SA - Pipeline by Target, 2016
  • TechnoPhage SA - Pipeline by Molecule Type, 2016
  • TechnoPhage SA - Pipeline Products by Mechanism of Action, 2016
  • TechnoPhage SA - Dormant Developmental Projects,2016

List of Figures

  • TechnoPhage SA - Pipeline by Top 10 Indication, 2016
  • TechnoPhage SA - Pipeline by Stage of Development, 2016
  • TechnoPhage SA - Monotherapy Products in Pipeline, 2016
  • TechnoPhage SA - Pipeline by Target, 2016
  • TechnoPhage SA - Pipeline by Molecule Type, 2016
  • TechnoPhage SA - Pipeline Products by Mechanism of Action, 2016
Back to Top